Rescuing kidney patients from early demise: role of anti-cytokine therapies

Affiliations

¹ Division of Nephrology and Hypertension, Department of Medicine, and Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Kidney Research Institute and Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.

Comment

T Alp Ikizler et al. Kidney Int. 2021 Dec.

. 2021 Dec;100(6):1152-1154.

doi: 10.1016/j.kint.2021.07.011. Epub 2021 Jul 22.

¹ Division of Nephrology and Hypertension, Department of Medicine, and Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Kidney Research Institute and Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.

No abstract available

Keywords: cardiovascular disease; chronic kidney disease; inflammation.

Comment on

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, Libby P, Davidson M; RESCUE Investigators. Ridker PM, et al. Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17. Lancet. 2021. PMID: 34015342 Clinical Trial.